|
Post by kc on Oct 6, 2017 11:39:58 GMT -5
Maxim raised price target to $7. May help! Concerned that Maxim is not a pump and dump boiler shop. But it's working and finding new buyers.
|
|
|
Post by kc on Oct 5, 2017 11:10:35 GMT -5
6,556,765 real time shares in the first 60 mins of trade. tracking for 36 million share day now with this volume. so perhaps half that? we will see.
cello, you are my new best friend, good point. point out everything you see and think.
MIKE C IS LEE IACOCCA. Just wait till the Street really discovers this stock and Afrezza. I can hardy wait for the first Cramer interview with Mike C. I don't care for Cramer in particular but no one can deny the visibility an interview can bring. Any show but Jim Crapper. Charles Payne on Fox business or Neil cavuto would be better
|
|
|
Post by kc on Oct 5, 2017 11:08:46 GMT -5
4.5 million shares in 15 minutes. Wow. We are on the CNBC ticker this morning. What will Jim Crapper say about That?
|
|
|
Post by kc on Oct 5, 2017 0:25:30 GMT -5
If you were Large Pharma...... How would you value SABOTAGE a potential drug/delivery system that could disrupt current therapy for one of the largest subsets of the industry and potentially change current uber profitable algorithms of treatment. Concurrently, how do you value SABOTAGE a delivery system that was able to accomplish this which could be used on perhaps tens or hundreds of drugs improving onset and action? Place regulatory barriers intended to slow progression of advancement of the drug. Cast dispersion on the efficacy and safety of the drug. Partner and take control without ever marketing a single ad about the drug. Impose expansion and future contractual obligations for supply. With control, market only to the smallest subset of the patient population. Withdraw support leaving company with few assets, extremely diluted shareholders letting market forces free to continue siege. Significantly reduce the patent life of intellectual property making the product less valuable. Force ultimate Bankruptcy and pick up the pieces. Am I cynical? Of course, I am a MNKD shareholder! Have you ever witnessed a drug/deliver system with such potential ignored by BP? Have you ever witnessed such a concerted effort in financial blogs and pundits to discredit such a product? Is it a perfect product, no. But it works and provides benefits not seen with competitive products. Time will also show that it will decrease morbidity and mortality in PWD. Thats what it is all about! I'm cynical but hopeful since we are still standing, and I am impressed so far by the actions and success of management. In the end and when successful, this will be written as a real life David vs Goliath story! I really feel Matt doesn’t get the recognition he deserves stepping into the CEO role when he did. He set a lot of the positive things happening now in motion. His claim of an “EPIC turnaround” is feeling more and more like reality. His comment about “position of strength” referenced the superior performance of Afrezza, not the financial position of the corporation at the time. I am with you! I hope that one day in the postmortem of how the turnaround took place we find that Matt had a big role in the turnaround. I believe he was a good man but we need somebody stronger and thankful we had Mike Castagna there ready to make the turn around.
|
|
|
Post by kc on Oct 4, 2017 16:25:41 GMT -5
In play as the blood is in the water. Something is in the horizon. Only the board and management knows what is about to unfold. AFREZZA is a great product the best is yet to happen.
|
|
|
Post by kc on Oct 4, 2017 8:01:24 GMT -5
sorry whats the omg here? maybe i am out of the loop. If he covers us on Half Time or Fast Money I’m going to faint! I’ve been telling him about MNKD:-) Flying to Seattle I was watching CNBC he didn’t mention it but it will be great if he does.
|
|
|
Post by kc on Oct 4, 2017 7:58:57 GMT -5
Been tied up in meetings Tuesday in Seattle just noticed this today. That is a big endorsement.
|
|
|
Post by kc on Oct 2, 2017 14:00:52 GMT -5
There was a rumor last Friday that Merck already gave an offer to MNKD board. I would think it's better to fund MNKD instead of acquiring it. To acquire a company you have to pay good premium, while to fund a company you usually get good discount in SP. You could do a layered buy into a company much like Medtronic is doing with Mazor Robotics. or the they Devil Sanofi did with Regeneron. I am sure that is what Al Mann wanted in the first place. Was a buy-in and not a buy-out.
|
|
|
Post by kc on Oct 2, 2017 11:42:28 GMT -5
What we really need is institutional investment. Then we know that the company is on more solid footing.
|
|
|
Post by kc on Oct 1, 2017 23:41:11 GMT -5
Some kind of deal got done by Sunday afternoon it's time to announce it Monday morning. Hoping for the best
|
|
|
Post by kc on Oct 1, 2017 17:58:22 GMT -5
One Pre-market Monday we will get some exciting news. Maybe this time it will be very exciting. Bad news normally After-hours and good news Pre-Market Monday's.
|
|
|
Post by kc on Oct 1, 2017 17:44:09 GMT -5
Now if somebody has the time to see what other Big Pharma has an announcement for the same time in the AM.
|
|
|
Post by kc on Oct 1, 2017 14:17:19 GMT -5
The imaginary Pink elephant
|
|
|
Post by kc on Oct 1, 2017 12:04:17 GMT -5
Oh guess what:-) Mike just tweeted again. It’s really interesting, but I’m not telling. Do your own DD:-)) Oh my there is a hidden message on this tweet....
|
|
|
Post by kc on Oct 1, 2017 11:59:35 GMT -5
Will Andrea be returning? Is her husband still with MannKind?
|
|